Leaders In Gene Therapy to Gather In Boston For The 5th Annual Next Generation Gene Therapy Vectors Summit

July 30–31, 2025 | Boston, MA — The 5th Annual Next Generation Gene Therapy Vectors Summit is all set to take place on July 30–31, 2025, in Boston, Massachusetts. This much-anticipated event will bring together global leaders and innovators in the field of gene therapy to explore the future of vector design, development, and clinical translation.

With 2024 witnessing major breakthroughs and investments such as Novartis’ $1.1 billion acquisition of Kate Therapeutics and the billion-dollar partnership between Roche and Dyno Therapeutics, this summit comes at a pivotal time. It is the only dedicated platform for professionals working specifically on viral and non-viral gene therapy vectors. The event will serve as a hub for sharing technical insights, transforming vector design and selection processes, and accelerating the path from lab to clinic.

Designed in collaboration with the gene therapy vector community, the summit offers a focused and collaborative environment where attendees can connect with leading experts from Spark Therapeutics, Novartis, 4D Molecular Therapeutics, Apertura Gene Therapy, and Coave Therapeutics. The agenda will highlight innovative strategies such as AI-driven vector engineering, rational capsid and payload design, and cost- and time-efficient approaches to non-clinical testing and manufacturing. The overarching goal is to help companies achieve safer and more effective gene therapies that can reach broader patient populations.

This year’s summit will feature over 20 expert speakers, with more than 10 new companies taking the stage for the first time. More than 40 companies will be represented, and over 60 attendees will have the opportunity to network, share challenges, and gain practical insights.

Some of the prominent speakers include Daniel Cohen, Head of Vector Optimization at Spark Therapeutics, Inc.; Eric Kelsic, Co-Founder & CEO of Dyno Therapeutics; Jorge Santiago-Ortiz, Senior Director, CMC at Apertura Gene Therapy; Lolita Petit, Chief Scientific Officer at Coave Therapeutics; Ralf Schmid, Associate Director - Pre-Clinical Research at Novartis AG; and Roxanne Croze, Senior Director at 4D Molecular Therapeutics.

The 5th Next Generation Gene Therapy Vectors Summit is more than just an industry event—it’s a catalyst for collaboration, innovation, and progress in vector science. Those committed to advancing gene therapy and delivering real solutions to patients are encouraged to attend.

For registration and more information, visit: 5th Annual Next Generation Gene Therapy Vectors Summit